

Milestones 2022



Dear Friends,

Another monumental year has passed at Dana-Farber, one that is all the more special as we celebrated our 75th anniversary, marking 75 years of groundbreaking scientific discoveries, advancements in cancer care, and extraordinary contributions to eradicating cancer globally.

As they have since 1948, our exceptional faculty continue to contribute to innovation on a national and even international scale. In 2022, Dana-Farber joined the Parker Institute for Cancer Immunotherapy Network, the leading network of immuno-oncology expertise in the world. Through this partnership, Dana-Farber will expand opportunities to collaborate with top research institutions, maximize the scientific value of discoveries, and translate those discoveries into more effective cancer immunotherapies.

We made further strides in prevention and early detection with new insights into precursor conditions and potential blood tests for new forms of cancer. And new discoveries are advancing targeted therapies for both adults and children in a variety of cancers. All of these efforts are supported by The Dana-Farber Campaign, our ambitious, multi-year fundraising effort to prevent, treat, and defy cancer.

Breakthroughs in cancer care mean nothing if that care does not reach every patient who needs us right now. To that end, we are doing everything we can to further improve inclusion, diversity, and equity in the delivery of our health care. In the past year alone, our Cancer Care Equity Program has doubled in size, thanks to philanthropic support and Institute funding. We led several studies to identify new, research-based strategies for addressing health care inequities, and expanded access to more patients through new facilities and partnerships here and around the globe.

All of these achievements are in service to what Dr. Sidney Farber started 75 years ago: a legacy of bold, audacious ideas that have led to revolutionary advancements made possible by you, our many friends and supporters. You continue to play an invaluable role as we strive to fulfill Dr. Farber's vision, and for that, we thank you.

Sincerely,

A handwritten signature in black ink, appearing to read 'Laurie H. Glimcher'.

Laurie H. Glimcher, MD
President and CEO, Dana-Farber Cancer Institute
Richard and Susan Smith Professor of Medicine, Harvard Medical School



Revolutionary Science

Progress for Early Detection

Dana-Farber scientists developed new blood tests that can precisely detect tumor DNA—in Wilms tumor, a rare form of pediatric kidney cancer, and in recurrent HPV-driven oropharyngeal cancer—marking a major advancement in detecting these cancers early.

Pediatric Precision Medicine

A Dana-Farber-led study evaluating the use of molecular tumor profiling in pediatric patients revealed a high rate of genetic alterations with potential for treatment with precision cancer drugs, challenging previously held wisdom that profiling pediatric solid tumors would not yield actionable results.

Key Target Identified

As part of an international collaboration, Dana-Farber chemists and structural biologists have discovered that a gene called FOXR2, normally turned off in most tissues, is activated in 70% of all cancers—opening a new avenue for targeted treatments in many disease areas.

Enhancing Genetic Testing

Dana-Farber developed an online tool that can accurately identify people who should undergo testing for inherited genetic changes that raise the risk of certain cancers. The tool could change the model for referring patients and families for genetic testing and counseling.

Insight into Precursor Condition

Two Dana-Farber studies uncovered the true cause of Barrett's esophagus, a precursor to esophageal cancer. The findings correct a long-held misconception about the disease, potentially offering new approaches to therapy and prevention.

Solving a Crucial Pathway

In a collaborative study, Dana-Farber researchers solved the structure of an important complex of RAS-pathway proteins, which drives tumor growth in about 25% of all cancer patients. This discovery suggests potential new binding sites for cancer drugs, a major step forward for a historically difficult-to-target complex.



Nurses in Dana-Farber's Jimmy Fund Clinic dress up for "Zoo Week."

Extraordinary Care

Expanding Access for Southern New England

Dana-Farber opened a new facility in Foxborough, Mass., to better serve patients in southern Massachusetts and Rhode Island. The new space at Patriot Place offers the same services and resources provided to adult patients in Boston, closer to where patients live.

Outpatient CAR T-Cell Therapy

To increase comfort and convenience for patients, Dana-Farber launched an outpatient program to administer CAR T-cell therapy to eligible patients, a milestone for this revolutionary immunotherapy that normally requires a week-long stay in the hospital.

New Partnership in the Midwest

The Christ Hospital Health Network, located in Ohio, became a member of the Dana-Farber Brigham Cancer Care Collaborative, bringing Dana-Farber's world-class cancer care to the Midwest for the very first time and relieving the burden of cancer for more patients on a national level.

Top Doctors

Boston magazine named more than 110 physicians and surgeons affiliated with Dana-Farber Cancer Institute to its annual "Top Doctors" guide, recognizing their expert and compassionate care.

To learn more about our world-class research and patient care, or to get involved, please visit: Dana-Farber.org | JimmyFund.org | DefyCancer.org

Follow us: @Dana-Farber | @TheJimmyFund | @DefyCancer






Nikhil Wagle, MD (above), and Eliezer Van Allen, MD, were honored with the Trailblazer Prize for Clinician-Scientists by the Foundation for the National Institutes of Health in 2022, for their considerable contributions to cancer research and care.

THE IMPACT OF YOUR GIVING

Mike's Story



When Mike James walks into work at Boston Adult Technical Academy, he sees an inspiring sign painted by the students: Together, We Can. That philosophy helped James stay positive after he was diagnosed with early stage non-small cell lung cancer. Coworkers, family, and his care team at Dana-Farber saw him through his participation in a groundbreaking clinical trial.

Non-small cell lung cancer has a high risk of recurrence, even after a tumor is surgically removed. But Dana-Farber's CheckMate 816 clinical trial, which combined an immunotherapy drug with standard chemotherapy to shrink the tumor before surgery, provided James with a clean bill of health and led to FDA approval of a new treatment for patients like him.

Now, James and his wife, Andrea, "seize the day," taking every opportunity they can to travel. "I'm a cancer survivor," James says. "I've learned that every day matters. There's no more wasting time. You have to grab life and do what you want to do."

Exceptional Expertise

#4 in the World for Cancer

Dana-Farber Cancer Institute was named the #4 cancer hospital in the world by *Newsweek* in its new World's Best Specialized Hospitals rankings.

Top in New England, Top 4 Nationwide

Dana-Farber Cancer Institute has been the top-ranked cancer hospital in New England by *U.S. News & World Report* for 22 consecutive years, and is the only cancer center in the country ranked in the top 4 for both adult and pediatric cancer programs.

Advancing the Public Good

Gordon Freeman, PhD, and Matthew Meyerson, MD, PhD, were elected to the American Academy of Arts & Sciences in recognition of their work to advance the public good through cancer research.

Inclusive Space for LGBTQ+ People

Dana-Farber was named a 2022 LGBTQ+ Healthcare Equality Leader by the Human Rights Campaign Foundation in the nation's foremost benchmarking survey of health care facilities on policies and practices dedicated to the equitable treatment of LGBTQ+ patients, visitors, and employees.

Center of Excellence

The Society of Nuclear Medicine and Molecular Imaging designated Dana-Farber as a Comprehensive Radiopharmaceutical Therapy Center of Excellence, a testament to the Institute's work to further the field of nuclear medicine.

Community Impact

Dana-Farber was recognized with the Community Impact Award by Family Aid Boston in recognition of the Institute's work to expand access for Boston's most vulnerable residents.

At Dana-Farber we are committed to an inclusive community where human differences are valued and celebrated, and where all are welcome. We work every day to create an innovative, caring, and inclusive environment where each patient, family, and staff member feels valued and respected.

Dana-Farber and the Jimmy Fund share patient stories which may include descriptions of actual medical results. Dana-Farber provides personalized care for each patient based on their unique needs; their experiences and results will vary.

To be removed from our mailing list, please contact: Dana-Farber Cancer Institute & The Jimmy Fund, Division of Philanthropy, 10 Brookline Place West, 6th Floor, Brookline, MA 02445-7226; 617-632-3019 or 800-52-JIMMY; or visit JimmyFund.org/opt-out.

Dana-Farber Cancer Institute & The Jimmy Fund
Division of Philanthropy
10 Brookline Place West, 6th Floor
Brookline, MA 02445-7226



DCPUB2235614

William G. Kaelin Jr., MD, received the Harriet P. Dustan Award for Outstanding Work in Science as Related to Medicine from the American College of Physicians.



Pasi Jänne, MD, PhD, received the 50th Griffuel Award from the ARC Foundation for Cancer Research in France for his work in EGFR-mutant lung cancer.



Irene Ghobrial, MD, was awarded the William Dameshek Prize by the American Society of Hematology in recognition of her research on the mechanisms underlying myeloma progression.



Milestones 2022